In early October 2019, the Franklin lab published their research in Cell Stem Cell on oligodendrocyte progenitor cells (OPCs). OPCs produce oligodendrocytes and the failure to produce them is related to the neurodegeneration in multiple sclerosis (MS). They found as adult rodent OPCs age, their differentiation potential decreases and they fail to respond to pro-differentiation signals, which is associated with many of the indicators of cellular aging. They then found that alternate-day fasting or treating the rodents with metformin has the ability to reverse this, restore aged OPCs regeneration capacity, and allow them to respond to differentiation signals again. These results offer insights into potential therapeutic treatments for MS and other disorders involving myelination.
Reyvow is an oral tablet used for the acute treatment of migraines; it is not a preventative treatment for migraines. It has a high affinity to the 5HT1F receptor and while it is believed that its agonist effects at the receptor, its exact mechanism of action is unknown.
Migraines can be a debilitating condition that can cause complications for everyday living. Treating migraines can be difficult, as the causes of migraines are varied and can be difficult to determine. As such, the greater a variety of treatments that can be offered to those that suffer from migraines, the greater a likelihood that all patients will be able to find a viable option, especially those that struggle to find a way to prevent migraines.